Press coverage about Cytosorbents (NASDAQ:CTSO) has trended positive recently, Accern reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cytosorbents earned a news sentiment score of 0.28 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 44.6337044019052 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
- What You Must Know About Cytosorbents Corporation’s (NASDAQ:CTSO) Financial Strength (finance.yahoo.com)
- What Kind of Returns are Cytosorbents Corporation (NasdaqCM:CTSO) Shares Generating? (derbynewsjournal.com)
- Cytosorbents Corporation (CTSO) Trades at $8.10 Forming Bullish Double Top Pattern (thecasualsmart.com)
- What’s in Cytosorbents Corporation (CTSO) After Forming Bullish Double Top Pattern? (malibureport.com)
- New Research: Key Drivers of Growth for Lincoln Electric, Cytosorbents, Materion, Fortune Brands Home & Security … (globenewswire.com)
Several equities analysts have recently commented on the stock. HC Wainwright set a $14.00 price objective on shares of Cytosorbents and gave the stock a “buy” rating in a report on Friday, March 9th. Maxim Group set a $12.00 price objective on shares of Cytosorbents and gave the stock a “buy” rating in a report on Friday, March 9th. Cowen set a $9.00 price objective on shares of Cytosorbents and gave the stock a “buy” rating in a report on Thursday, March 8th. B. Riley restated a “buy” rating and issued a $11.25 price objective on shares of Cytosorbents in a report on Thursday, January 25th. Finally, ValuEngine upgraded shares of Cytosorbents from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th. Six research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus target price of $11.05.
CTSO traded down $0.10 during trading hours on Tuesday, hitting $8.00. 128,600 shares of the company’s stock were exchanged, compared to its average volume of 175,875. Cytosorbents has a 12-month low of $3.30 and a 12-month high of $8.35. The company has a market cap of $242.86 million, a P/E ratio of -25.00 and a beta of -0.08. The company has a quick ratio of 2.54, a current ratio of 2.64 and a debt-to-equity ratio of 0.58.
Cytosorbents (NASDAQ:CTSO) last announced its earnings results on Thursday, March 8th. The medical research company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.02). Cytosorbents had a negative return on equity of 118.07% and a negative net margin of 52.08%. The business had revenue of $4.65 million for the quarter, compared to analysts’ expectations of $4.56 million. research analysts forecast that Cytosorbents will post -0.47 earnings per share for the current year.
In related news, CFO Kathleen P. Bloch sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $8.00, for a total transaction of $80,000.00. Following the sale, the chief financial officer now directly owns 268,870 shares of the company’s stock, valued at approximately $2,150,960. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Kathleen P. Bloch sold 11,176 shares of the company’s stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $8.25, for a total transaction of $92,202.00. Following the sale, the chief financial officer now directly owns 261,246 shares in the company, valued at $2,155,279.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,400 shares of company stock worth $182,300. 6.90% of the stock is owned by insiders.
Cytosorbents Company Profile
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.